Navigation Links
DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference

REHOVOT, Israel, May 29, 2007 /PRNewswire/ -- D-Pharm announced today that the results of the Phase IIb trial for its neuroprotective compound DP-b99 in the treatment of acute ischemic stroke patients will be presented at the European Stroke Conference. The data will be presented by the study's German principal investigator Prof. H. C. Diener, on Thursday May 31st at 14.30 in the Carron Room, at the Scottish Exhibition Conference Center in Glasgow. The abstract for the presentation may be viewed using the European Stroke Conference search engine at: http://www.eurostroke.eu/gla_searching.htm

DP-b99, discovered and developed by D-Pharm, is a unique neuroprotective drug that addresses an array of damaging processes occurring in the brains of stroke patients. A Phase IIb multicenter, double blind, placebo controlled, randomized trial to assess DP-b99's effect on stroke outcomes was completed in December 2006. The study enrolled 150 ischemic stroke patients with signs of cortical involvement and NIH Stroke Scale (NIHSS) score of 7-20. DP-b99 (1mg/kg/day) or placebo was administered i.v. within 1-9 hours of stroke-onset as a 4-day course of once-daily 2hr infusions with a 90-day follow-up.

The main pre-defined efficacy endpoints in the study included: the change in National Institute of Health Stroke Scale (NIHSS) score from day 0 to day 90; the percent of patients completely recovered after stroke (score 0 or 1, or same as pre-stroke) at day 90 as assessed by the modified Rankin scale or NIHSS.

The day 90 recovery rate in the DP-b99 treated group was two times higher than in the placebo group. Specifically, the recovery rate in the DP-b99 and placebo groups per modified Rankin scale was 30.6% and 16.0% (p=0.05), per NIHSS was 23.6% and 12.0% (p=0.08), and defined by either scale was 37.5% and 18.7% (p=0.02), respectively
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase IIb Trial Results Presented the European Stroke Conference
(Date:8/29/2014)... Does your doctor know what you,re smoking?  Chances are, probably ... the over 112,000 currently registered patients under Colorado,s ... roughly 20,300+ active physicians listed with the Colorado Dept of ... though a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... , August 29, 2014 ... by Product & Services (Equipment, Reagent, Primer, Probe, ... (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) ... the global Oligonucleotide Synthesis Market is expected to ... in 2014, growing at a CAGR of 9.8% ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Institute researchers are first to associate unique DNA changes ... with several types of renal cell carcinoma, ... (VAI),researchers have identified unique DNA changes in each of several ... kidney cancer in,adults. These findings could aid in the diagnosis ...
... Sept. 12 Bionovo, Inc.,(Nasdaq: BNVI ) ... the journal for,the American Society for Pharmacology and ... Vitro Metabolism of,Liquiritigenin, a Bioactive Compound Isolated from ... Liquiritigenin is one of the active compounds of ...
Cached Medicine Technology:VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3
(Date:8/30/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... 30 August 2014: Transvenous lead extraction (TLE) is clinically ... data from the European Lead Extraction ConTRolled (ELECTRa) registry ... 2014 by Dr Maria Grazia Bongiorni, chair of the ... of cardiac implantable electronic devices (CIED) implant procedures has ... number of complications has increased and leads are often ...
(Date:8/30/2014)... The new review published by Daily Gossip ... Karen Brimeyer, who wanted to make her guide accessible to ... is now easy to find in the form of an ... the author of the new method shares all her tips ... writes in its review that the leaky gut syndrome can ...
(Date:8/30/2014)... Jake W., 18, is completing his high school degree ... Adventures transition program known as Beyond the Basics. ... actually start on a real career path,” said Jake. “ ... He has six months of sobriety under his belt after ... continue on to the Beyond the Basics transition program notes ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... of Nutrition Elaine Rush states that consumption of energy ... as caffeine contributes to obesity. // ,The ... caffeine and guarana (which also contains caffeine) causes the ... lemonade. "These results could have huge implications when you ...
... Haven, Conn. – Ever since the treatment methodologies to treat heart ... difference in survival between male and female patients, whites and blacks ... of the largest national studies on this topic in the US, ... treatments’ - such as aspirin, beta-blockers and reperfusion therapy ...
... CA -- Successful eradication of Helicobacter may not prevent ... left behind. This was reported by Research led by ... Medicine., ,The paper by Mueller et al., "The ... the pathogenesis of Helicobacter-induced MALT lymphoma," appears in the ...
... of American Journal of Psychiatry had said that both ... in the brain structures that can later affect the ... paying attention to something and processing information. The results ... ,Methamphetamine abuse is linked with HIV, hepatitis C, and ...
... developing countries have said that it is possible to help ... supplement of zinc. The research report was published in the ... 2000 to 2003, pneumonia caused 2 million of 10·6 million ... a further 1·9 million deaths in this group annually. Daily ...
... a common problem among children and adolescents. Most of the ... more interested in dragging them for treatment. A new study ... given to identify the victim’s feelings of either shame or ... treatment outcomes., ,Shame is the tendency to feel bad ...
Cached Medicine News:Health News:Obesity Can Be Caused By Consumption Of Energy Drinks 2Health News:Women and Black Patients have less chances to survive a Heart Attack 2Health News:Helicobacter pylori Antibiotic Treatment of Peptic Ulcer May not Prevent Gastric lymphomas 2Health News:Changes In Brain Structure From Methamphetamine Abuse And HIV Infection 2Health News:Effective Treatment Of Drug Abuse Dependent On Feelings Of Shame Or Guilt 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: